(Q37776832)

23 August 2017

1 reference

title

The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains (English)

1 reference

23 August 2017

main subject

Staphylococcus aureus

1 reference

1 reference

1

Fred C Tenover

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20674281

14 June 2024

publication date

31 July 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0924857910002463?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

https://api.elsevier.com/content/article/PII:S0924857910002463?httpAccept=text/plain

14 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

International Journal of Antimicrobial Agents

14 June 2024

published in

1 reference

23 August 2017

volume

36

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

303-306

1 reference

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus

14 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

14 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides

14 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

14 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

14 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance

14 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

14 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.

14 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

14 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

A microdilution plating method for population analysis of antibiotic-resistant staphylococci

14 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

14 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides

14 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.

14 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejuni, and gram-negative bacteria resistant to antimicrobial agents

14 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus

14 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections

14 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides

14 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

14 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides

14 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.

14 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05

14 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.

14 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

14 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.

14 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus

14 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus

14 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.06.005

14 June 2024

Identifiers

1 reference

23 August 2017

1 reference